Plain language summary
In the human body, the thyroid gland has the highest content of selenium in proportion to weight. A sufficient intake of selenium is mandatory in order to avoid disturbance of the thyroid hormone balance. The primary aim of this study was to evaluate the impact of selenium and coenzyme Q10 (CoQ10) supplementation on thyroid hormone levels, cardiovascular mortality, and quality of life in elderly individuals. This study was a randomised, double-blind, placebo-controlled trial involving 443 elderly participants (average age 78 years) over a period of 4 years. Results showed: - elevated thyroid stimulating hormone (TSH) and low fT3 levels in those elderly people with the lowest selenium intake. - selenium/CoQ10 supplementation resulted in significantly increased fT3 and decreased fT4 levels. - lower TSH levels were associated with reduced CV mortality and improved measures of health-related quality of life. Authors concluded that a substantial part of the study population might suffer from suboptimal thyroid function due to an example of an insufficient selenium intake.
Expert Review
Conflicts of interest:
None
Take Home Message:
- Low selenium was associated with elevated TSH levels and significantly increased CVM within 10 years.
- Supplementation with selenium and CoQ10 may be beneficial for those identified with even a mild selenium deficiency for reduced CVM and improved Hr-QoL.
Evidence Category:
-
X
A: Meta-analyses, position-stands, randomized-controlled trials (RCTs)
-
B: Systematic reviews including RCTs of limited number
-
C: Non-randomized trials, observational studies, narrative reviews
-
D: Case-reports, evidence-based clinical findings
-
E: Opinion piece, other
Summary Review:
Introduction
- Important metabolic pathways in the cells require adequate supply of coenzyme Q10 (CoQ10) and selenoproteins for optimal functioning, however endogenous CoQ10 production decreases with age.
- Previous research reports selenium and CoQ10 supplementation reduced cardiovascular mortality (CVM) and improved health related quality of life (Hr-QoL) in the elderly with low selenium intake.
- Less focus has been on low selenium in thyroid hormone regulation and the association with CVM and Hr-QoL, therefore this study aimed to evaluate an intervention of selenium and CoQ10 on thyroid hormonal status, CVM and Hr-QoL.
Methods
- A randomised, placebo-controlled, double-blind 4-year study was executed with 414 participants aged between 70-88, identified with low selenium.
- 210 individuals were randomised to active intervention of selenium yeast (200μg/day) and CoQ10 (200mg/day) and 204 to placebo.
- Changes in hormone concentrations were assessed using t-tests, repeated measures of variance and ANCOVA, while CVM and Hr-QoL were evaluated with Short Form-36 (SF-36).
Results
- In the supplementation group there was a significant increase in free triiodothyronine (fT3) and reverse triiodothyronine (rT3), and a significant decrease in free thyroxine (fT4) and thyroid stimulating hormone (TSH) levels compared with placebo (p=0.03 in each).
- In the placebo group, TSH and fT4 above median values were correlated with increased 10-year CVM compared with mortality risk in those with TSH and fT4 below median (p<0.04 in both).
- In the supplementation group there was no difference in mortality rate according to TSH and fT4 levels.
- In the placebo group, TSH > and fT3 < median were correlated with a decline in items of Hr-QoL such as ‘vitality’, ‘bodily pain’ and social function’ as well as ‘composite physical score’ compared to those with TSH < and fT3 > median over 4 years.
- In the supplementation group there was no difference in Hr-QoL according to TSH and fT3 levels.
Conclusion
- Selenium and CoQ10 supplementation has a positive effect on thyroid hormones with reduced CVM and improved Hr-QoL in older adults.
- Changes in thyroid hormones may be explained by increased selenium-dependent deiodinases, important enzymes in thyroid hormone homeostasis.
Clinical practice applications:
- In light of these findings, routine testing of thyroid hormone levels of TSH, T3 and T4 is advisable.
- Individuals with low selenium concentrations presented with significantly higher TSH levels and higher CVM compared to those with higher selenium, thus monitoring those who may be at risk of low selenium status, may be prudent.
- Supplementation with selenium may help to restore deiodinase activity and thyroid hormone balance as well as have clinical implications for reduced CVM and inflammation.
Considerations for future research:
- Further research is needed to explore the impact of selenium status on human physiology.
- As results are reported as hypothesis generating, future research is necessary and would benefit from a more diverse ethnicity rather than only Caucasians, as well as a broader age range. Evaluation of hypothyroidism symptoms, as well as general health symptoms and risk factors for CVM would be of interest.
- Evaluation of C-reactive protein concentration in relation to T3 levels and relationship between inflammation, oxidative stress and selenium may be helpful.
Abstract
BACKGROUND Selenium-dependent deiodinases play a central role in thyroid hormone regulation and metabolism. In many European countries, insufficient selenium intake may consequently lead to adverse effects on thyroid function. In this randomised placebo-controlled double-blind study, we examined the effect of supplementation with selenium and coenzyme Q10 on thyroid hormonal status, cardiovascular (CV) mortality and health-related quality of life (Hr-QoL). METHODS Free T3, free T4, reverse T3, and TSH were determined in 414 individuals at baseline, and the effect of selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day) supplementation on hormone concentrations, CV mortality and Hr-QoL was evaluated after 48 months using Short Form 36 (SF-36). Pre-intervention plasma selenium was low, mean 67 µg/L, corresponding to an estimated intake of 35 µg/day. Changes in concentrations of thyroid hormones following the intervention were assessed using T-tests, repeated measures of variance, and ANCOVA analyses. RESULTS In the total population, the group with the lowest selenium concentration at baseline presented with significantly higher levels of TSH and lower levels of fT3 as compared to subjects with the highest selenium concentration. Supplementation with selenium and coenzyme Q10 for 4 years significantly increased fT3 and rT3, decreased fT4, and diminished the increase in TSH levels compared with placebo treatment (p = 0.03, all). In the placebo group, TSH and fT4 values above the median were associated with an increase in 10-year CV mortality, as compared with the mortality rate among those with TSH and fT4 below the median (p < 0.04, both), with no difference in mortality rate according to TSH and fT4 levels in the active intervention group. Similarly, TSH > median and fT3 < median were associated with a decline in mental Hr-QoL measures vs. TSH < and fT3 > median in the placebo group during 4 years of follow-up, but this was wiped out in the active group. CONCLUSIONS Supplementation with selenium and coenzyme Q10 had a beneficial effect on thyroid hormones with respect to CV mortality and Hr-QoL outcomes. The initial deficient selenium status was associated with an impaired thyroid function and the changes in thyroid hormone levels can be explained by increased activity of deiodinases. We conclude that a substantial part of the elderly study population might suffer from suboptimal thyroidal function with adverse clinical implications due to selenium deficiency. TRIAL REGISTRATION This study was registered at ClinicalTrials.gov and has the identifier NCT01443780. Since it was not mandatory to register at the time the study began, the study has been registered retrospectively.
Methodological quality
Jadad score
:
4
Allocation concealment
:
Yes